Boston Scientific Corp. is delaying its previously communicated timeline for the commercialization of its Lotus Edge aortic valve system. Initially, the company was going to file for a PMA for the device in January and relaunch the device in Europe by the end of 1Q18. This is the latest setback the Marlborough, Mass.-based company has faced with Lotus as it seeks to obtain a significant foothold in the transcatheter aortic valve replacement (TAVR) market, dominated by Edwards Lifesciences Corp. and Medtronic plc. Read More
